

ORBOTECH LTD
Form 6-K
June 30, 2009

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

For the month of June 2009

Commission File Number **000-12790**

ORBOTECH LTD.

(Translation of Registrant's name into English)

SANHEDRIN BOULEVARD, NORTH INDUSTRIAL ZONE, YAVNE 81101, ISRAEL

(Address of principal executive offices)

Indicate by check mark whether the Registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F _____

Form 40-F _____

Indicate by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): _____

Indicate by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____

Indicate by check mark whether by furnishing the information contained in this Form, the Registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes _____

No _____

Edgar Filing: ORBOTECH LTD - Form 6-K

Attached hereto and incorporated by reference herein is the following document:

1. Press release issued by the Registrant on, and dated, June 29, 2009, and entitled GE Amends Complaint in Dispute with Orbotech Ltd. .
* * * * *

This report on Form 6-K is incorporated by reference into the Registration Statements on Form S-8 (Registration No. 33-25782, Registration No. 33-78196, Registration No. 333-05440, Registration No. 333-06542, Registration No. 333-08404, Registration No. 333-09342, Registration No. 333-11124, Registration No. 333-12692, Registration No. 333-127979 and Registration No. 333-154394) of Orbotech Ltd. previously filed with the Securities and Exchange Commission.

FOR IMMEDIATE RELEASE

GE AMENDS COMPLAINT IN DISPUTE WITH ORBOTECH LTD.

YAVNE, ISRAEL June 29, 2009 ORBOTECH LTD. (NASDAQ/GSM SYMBOL: ORBK) today announced that on June 18, 2009, GE Healthcare, which describes itself as a unit of General Electric Company, amended its complaint against Orbotech Ltd. (the **Company**), originally filed on November 4, 2008, in the United States District Court for the Eastern District of Wisconsin. The amended complaint expands the U.S. litigation to include certain of the breach of contract claims at issue in the dispute requested to be referred to arbitration in Israel and requests compensatory, consequential, exemplary and punitive damages in an unspecified amount. The dispute relates, among other things, to a claim for damages related to an assertion that Orbotech Medical Solutions Ltd. (**OMS**) was obligated to supply GE Medical Systems Israel Ltd. (**GEMSI**) with CZT modules at a specific price per module pursuant to the terms of an agreement between the Company and GEMSI from December 2004 (such agreement was assigned to OMS and expired in December 2007) and a claim that OMS had an obligation to supply GEMSI with 850 CZT modules by specific dates. The Company continues to believe it has good arguments to dismiss the amended complaint as well as good arguments on the merits should the court determine it will hear the case and intends to defend the matter vigorously. For more information about this matter and the related arbitration matter in Israel, see the Company's Annual Report on Form 20-F for the year ended December 31, 2008, filed with the United States Securities and Exchange Commission.

About Orbotech Ltd.

Orbotech is principally engaged in the design, development, manufacture, marketing and service of yield-enhancing and production solutions for specialized applications in the supply chain of the electronics industry. Orbotech's products include automated optical inspection (AOI), production and process control systems for printed circuit boards (PCBs) and AOI, test and repair systems for flat panel displays (FPDs). The Company also markets computer-aided manufacturing and engineering (CAM) solutions for PCB production. In addition, through its subsidiary, Orbograph Ltd., the Company develops and markets character recognition solutions to banks and other financial institutions, and has developed a proprietary technology for web-based, location-independent data entry for check processing and forms processing; and, through its subsidiaries, Orbotech Medical Denmark A/S and Orbotech Medical Solutions Ltd., is engaged in the research and development, manufacture and sale of specialized products for application in medical nuclear imaging. Of Orbotech's employees, more than one quarter are scientists and engineers, who integrate their multi-disciplinary knowledge, talents and skills to develop and provide sophisticated solutions and technologies designed to meet customers' long-term needs. Orbotech maintains its headquarters and its primary research, development and manufacturing facilities in Israel, and more than 30 offices worldwide. Orbotech's extensive network of marketing, sales and customer support teams throughout North America, Europe, the Pacific Rim, China and Japan deliver its knowledge and expertise directly to customers the world over. For more information visit www.orbotech.com.

Except for historical information, the matters discussed in this press release are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These statements relate to, among other things, future prospects, developments and business strategies and involve certain risks and uncertainties. The words anticipate, believe, could, will, plan, expect and would and similar terms and phrases, including references to assumptions, have been used in this press release to identify forward-looking statements. These forward-looking statements are made based on management's expectations and beliefs concerning future events affecting Orbotech and are subject to uncertainties and factors relating to its operations and business environment, all of which are difficult to predict and many of which are beyond the Company's control. Many factors could cause the actual results to differ materially from those projected, including cyclicalities in the industries in which the Company operates, a sustained continuation or worsening of the worldwide economic slowdown, the timing and strength of product and service offerings by the Company and its competitors, changes in business or pricing strategies, changes in the prevailing political and regulatory framework in which the relevant parties operate or in economic or technological trends or conditions, including currency fluctuations, inflation and consumer confidence, on a global, regional or national basis and other risks detailed in the Company's SEC reports, including the Company's Annual Report on Form 20-F. The Company assumes no obligation to update the information in this press release to reflect new information, future events or otherwise, except as required by law.

COMPANY CONTACTS:

Adrian Auman
Corporate Vice President
Orbotech Ltd.
+972-8-942-3560

Michelle Harnish
Marketing Communications Manager
Orbotech, Inc.
+1-978-901-5120

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ORBOTECH LTD.

(Registrant)

By: /s/ Amichai Steimberg
Amichai Steimberg
Executive Vice President
and Chief Financial Officer
Date: June 30, 2009